Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1972 1
1978 1
1990 1
1991 2
1994 2
1995 1
1996 1
1998 1
2000 1
2002 5
2003 1
2004 1
2005 1
2006 5
2007 3
2008 2
2009 1
2010 2
2011 2
2012 7
2013 4
2014 3
2015 3
2016 8
2017 2
2018 3
2019 6
2020 15
2021 10
2022 7
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

88 results
Results by year
Filters applied: . Clear all
Page 1
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial.
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. Sledge GW Jr, et al. Among authors: hurt k. JAMA Oncol. 2020 Jan 1;6(1):116-124. doi: 10.1001/jamaoncol.2019.4782. JAMA Oncol. 2020. PMID: 31563959 Free PMC article. Clinical Trial.
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2--Advanced Breast Cancer.
Neven P, Johnston SRD, Toi M, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Haddad N, Hurt KC, Llombart-Cussac A, Sledge GW. Neven P, et al. Among authors: hurt kc. Clin Cancer Res. 2021 Nov 1;27(21):5801-5809. doi: 10.1158/1078-0432.CCR-20-4685. Epub 2021 Aug 10. Clin Cancer Res. 2021. PMID: 34376533
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P, Rugo HS, Tolaney SM, Iwata H, Toi M, Goetz MP, Kaufman PA, Lu Y, Haddad N, Hurt KC, Sledge GW Jr. Neven P, et al. Among authors: hurt kc. Breast Cancer Res. 2021 Aug 23;23(1):87. doi: 10.1186/s13058-021-01463-2. Breast Cancer Res. 2021. PMID: 34425869 Free PMC article. Clinical Trial.
Metabolomics in Prenatal Medicine: A Review.
Monni G, Atzori L, Corda V, Dessolis F, Iuculano A, Hurt KJ, Murgia F. Monni G, et al. Among authors: hurt kj. Front Med (Lausanne). 2021 Jun 25;8:645118. doi: 10.3389/fmed.2021.645118. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34249959 Free PMC article. Review.
Breast implant rupture: A sports trauma report.
Krajcová A, Hurt K, Kufa R, Molitor M. Krajcová A, et al. Among authors: hurt k. Ceska Gynekol. 2020 Winter;85(2):116-119. Ceska Gynekol. 2020. PMID: 32527105 Review. English.
Cystic fibrosis: management of haemoptysis.
Hurt K, Simmonds NJ. Hurt K, et al. Paediatr Respir Rev. 2012 Dec;13(4):200-5. doi: 10.1016/j.prrv.2012.01.003. Epub 2012 Feb 28. Paediatr Respir Rev. 2012. PMID: 23069116 Review.
International Forum on Gender Identification and Blood Collection: Responses.
Pandey S, Gorlin JB, Townsend M, Van Buren N, Leung JNS, Lee CK, van den Hurk K, Casamitjana N, Valles R, Alonso E, Miller YM, Richard P, Woimant G, Tiberghien P, Zhiburt E, Butler-Foster T, Goldman M, Nissen-Meyer LSH, Espinosa A, Kamel H, Bravo M, Filho LA, Pecego M, Germain M, Rabusseau I, Shinar E, Raz H, Choudhury N, Bhatnagar N, Hurt K, Lopez M, Reik RA, Nie Y, Hung Y, Pheello L, Dunbar N. Pandey S, et al. Among authors: hurt k. Vox Sang. 2022 Mar;117(3):E21-E43. doi: 10.1111/vox.13193. Epub 2021 Sep 20. Vox Sang. 2022. PMID: 34545590 No abstract available.
88 results